277 related articles for article (PubMed ID: 21827675)
1. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.
Ye Q; Loisiou M; Levine BL; Suhoski MM; Riley JL; June CH; Coukos G; Powell DJ
J Transl Med; 2011 Aug; 9():131. PubMed ID: 21827675
[TBL] [Abstract][Full Text] [Related]
2. IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.
Santegoets SJ; Turksma AW; Suhoski MM; Stam AG; Albelda SM; Hooijberg E; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; Powell DJ; June CH; de Gruijl TD
J Transl Med; 2013 Feb; 11():37. PubMed ID: 23402380
[TBL] [Abstract][Full Text] [Related]
3. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
4. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
6. TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.
Kongkaew T; Thaiwong R; Tudsamran S; Sae-Jung T; Sengprasert P; Vasuratna A; Suppipat K; Reantragoon R
J Immunol Methods; 2022 Apr; 503():113229. PubMed ID: 35101548
[TBL] [Abstract][Full Text] [Related]
7. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
[TBL] [Abstract][Full Text] [Related]
8. Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.
Forget MA; Malu S; Liu H; Toth C; Maiti S; Kale C; Haymaker C; Bernatchez C; Huls H; Wang E; Marincola FM; Hwu P; Cooper LJ; Radvanyi LG
J Immunother; 2014; 37(9):448-60. PubMed ID: 25304728
[TBL] [Abstract][Full Text] [Related]
9. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
[TBL] [Abstract][Full Text] [Related]
10. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
11. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.
Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM
Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
[TBL] [Abstract][Full Text] [Related]
13. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.
Suhoski MM; Golovina TN; Aqui NA; Tai VC; Varela-Rohena A; Milone MC; Carroll RG; Riley JL; June CH
Mol Ther; 2007 May; 15(5):981-8. PubMed ID: 17375070
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes.
Levin N; Kim SP; Marquardt CA; Vale NR; Yu Z; Sindiri S; Gartner JJ; Parkhurst M; Krishna S; Lowery FJ; Zacharakis N; Levy L; Prickett TD; Benzine T; Ray S; Masi RV; Gasmi B; Li Y; Islam R; Bera A; Goff SL; Robbins PF; Rosenberg SA
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38816232
[TBL] [Abstract][Full Text] [Related]
15. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
16. Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function.
Ollé Hurtado M; Wolbert J; Fisher J; Flutter B; Stafford S; Barton J; Jain N; Barone G; Majani Y; Anderson J
PLoS One; 2019; 14(8):e0216373. PubMed ID: 31398192
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy.
He J; Tang XF; Chen QY; Mai HQ; Huang ZF; Li J; Zeng YX
Chin J Cancer; 2012 Jun; 31(6):287-94. PubMed ID: 22257383
[TBL] [Abstract][Full Text] [Related]
20. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.
Hall M; Liu H; Malafa M; Centeno B; Hodul PJ; Pimiento J; Pilon-Thomas S; Sarnaik AA
J Immunother Cancer; 2016; 4():61. PubMed ID: 27777771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]